Syros Pharmaceuticals (SYRS) News Today → Does this make you sick? (From Allegiance Gold) (Ad) Free SYRS Stock Alerts $5.45 -0.03 (-0.55%) (As of 09:30 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:46 AM | americanbankingnews.comBrookline Capital Management Weighs in on Syros Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:SYRS)May 17 at 10:10 AM | marketbeat.comResearch Analysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:SYRS)Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Investment analysts at Brookline Capital Management boosted their FY2025 EPS estimates for Syros Pharmaceuticals in a research note issued to investors on Tuesday, May 14th. Brookline Capital Management analyst L. Cann now anticipates thatMay 17 at 6:49 AM | americanbankingnews.comQ2 2024 EPS Estimates for Syros Pharmaceuticals, Inc. Increased by HC Wainwright (NASDAQ:SYRS)May 17 at 6:15 AM | americanbankingnews.comFY2026 EPS Estimates for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Decreased by AnalystMay 17 at 5:41 AM | americanbankingnews.comStockNews.com Upgrades Syros Pharmaceuticals (NASDAQ:SYRS) to HoldMay 17 at 4:40 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS)May 16, 2024 | marketbeat.comFY2026 Earnings Forecast for Syros Pharmaceuticals, Inc. Issued By Brookline Capital Management (NASDAQ:SYRS)Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Stock analysts at Brookline Capital Management cut their FY2026 EPS estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Tuesday, May 14th. Brookline Capital Management analyst L. Cann now forecasts thatMay 16, 2024 | markets.businessinsider.comOptimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory AdvancementsMay 15, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Issues Earnings Results, Beats Estimates By $0.10 EPSSyros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. During the same quarter in the prior year, the business earned ($0.85) earnings per share.May 15, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Syros Pharmaceuticals (NASDAQ:SYRS)HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday.May 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Syros Pharmaceuticals's earningsMay 15, 2024 | finance.yahoo.comSyros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Syros Pharmaceuticals Inc Earnings CallMay 14, 2024 | msn.comSyros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77May 14, 2024 | msn.comSYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | businesswire.comSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 12, 2024 | marketbeat.comShort Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Drops By 22.0%Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,450,000 shares, a decline of 22.0% from the April 15th total of 1,860,000 shares. Based on an average daily trading volume, of 196,500 shares, the days-to-cover ratio is presently 7.4 days. Currently, 7.8% of the shares of the stock are sold short.May 12, 2024 | americanbankingnews.comSyros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on TuesdayMay 7, 2024 | businesswire.comSyros to Participate in Upcoming Investor ConferencesMay 7, 2024 | businesswire.comSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024May 2, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5.94Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Crosses Below 50 Day Moving Average of $5.94April 17, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday.April 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 9, 2024 | msn.comSyros jumps on FDA fast track tag for leukemia drugApril 9, 2024 | markets.businessinsider.comFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid LeukemiaApril 9, 2024 | businesswire.comSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionApril 3, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Receives Overweight Rating from Piper SandlerPiper Sandler reissued an "overweight" rating and issued a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday.April 3, 2024 | marketbeat.comSyros Pharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:SYRS)Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - HC Wainwright cut their Q1 2024 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a report issued on Monday, April 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.20) perApril 2, 2024 | businesswire.comSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a report on Monday.March 30, 2024 | marketbeat.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in MarchSyros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 1,740,000 shares, a growth of 31.8% from the February 29th total of 1,320,000 shares. Based on an average trading volume of 212,500 shares, the short-interest ratio is currently 8.2 days. Currently, 9.6% of the shares of the company are short sold.March 29, 2024 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | investing.comEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsMarch 29, 2024 | marketbeat.comSyros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Research analysts at Brookline Capital Management raised their Q1 2024 earnings estimates for Syros Pharmaceuticals in a research note issued to investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann now forecastsMarch 28, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by StockNews.comStockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday.March 28, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | marketbeat.comAnalysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:SYRS)Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Analysts at Brookline Capital Management issued their FY2028 earnings estimates for Syros Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann expects tMarch 28, 2024 | markets.businessinsider.comSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene TrialsMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 27, 2024 | markets.businessinsider.comSyros Pharmaceuticals earnings preview: what Wall Street is expectingMarch 27, 2024 | investorplace.comSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial DevelopmentsMarch 27, 2024 | businesswire.comSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateMarch 25, 2024 | finance.yahoo.comSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialMarch 21, 2024 | marketbeat.comSyros Pharmaceuticals (SYRS) to Release Earnings on WednesdaySyros Pharmaceuticals (NASDAQ:SYRS) will be releasing earnings before the market opens on Wednesday, March 27, Zacks reports.March 20, 2024 | businesswire.comSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024March 16, 2024 | finance.yahoo.comSYRS Apr 2024 10.000 callMarch 14, 2024 | marketbeat.comShort Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expands By 29.4%Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 1,320,000 shares, an increase of 29.4% from the February 14th total of 1,020,000 shares. Currently, 7.3% of the company's stock are short sold. Based on an average daily volume of 320,300 shares, the days-to-cover ratio is presently 4.1 days.March 11, 2024 | msn.comFibroGen appoints Deyaa Adib as Chief Medical OfficerMarch 9, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Share Price Crosses Below 50 Day Moving Average of $7.15Syros Pharmaceuticals (NASDAQ:SYRS) Shares Pass Below 50 Day Moving Average of $7.15 Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry SYRS Media Mentions By Week SYRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRS News Sentiment▼0.400.42▲Average Medical News Sentiment SYRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRS Articles This Week▼272▲SYRS Articles Average Week Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INCR News RENB News IMAB News SKYE News SGMT News RAPT News CTMX News CRVO News RGLS News MCRB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
